Table 1.
Detailed clinical and outcomes characteristics.
| Variables | N = 14 |
|---|---|
| Male/female | 6/8 |
| Age (years) | 56 (44–65) |
| Body mass index (kg/m2) | 26.8 (23.9–29.7) |
| Comorbidities | |
| Arterial hypertension | 5 (35.7%) |
| Diabetes mellitus | 2 (14.3%) |
| Obesity | 8 (57.1%) |
| Coronary artery disease | 0 (0%) |
| Chronic obstructive pulmonary disease | 1 (7.1%) |
| Charlson Comorbidity Index | 2 (1–3) |
| Smoking | 2 (14.3%) |
| Risk factors of PE | |
| Contraceptives | 0 (0%) |
| Immobilization/surgery during last 14 days | 8 (57.1%) |
| Malignancy | 4 (28.6%) |
| Prior PE or DVT | 0 (0%) |
| Clinical presentation | |
| Shock | 3 (21.4%) |
| Syncope or presyncope | 5 (35.7%) |
| Cardiac arrest | 2 (14.3%) |
| Respiratory failure (desaturation <92%) | 8 (57.1%) |
| Dyspnea | 12 (85.7%) |
| Chest pain | 1 (7.1%) |
| DVT at presentation | 9 (64.2%) |
| HR (per min) | 110 (100–120) |
| Respiratory rate (per min) | 32.5 (30–34) |
| SBP (mmHg) | 106 (90–127) |
| DBP (mmHg) | 73.5 (59–87.5) |
| Laboratory findings | |
| Troponin I positive at presentation | 14 (100%) |
| Troponin I concentration (ng/ml) | 59.4 (0.29–64.5) |
| D-dimers concentration (ng/ml) | 11900 (4244–17185) |
| NT-proBNP concentration (pg/ml) | 3993.5 (2457–47670) |
| Echocardiographic findings (4CH) | |
| RV diameter (mm) | 46 (44–46) |
| LV diameter (mm) | 34 (32–26) |
| RV/LV ratio (mm) | 1.3 (1.3–1.5) |
| TAPSE (mm) | 16 (13–19) |
| LV ejection fraction | 55 (50–55) |
| RV systolic pressure | 60 (42–62) |
| In-hospital death | 1 (7.1%) |
| Death of RV insufficiency | 0 (0%) |
| Death during follow-up | 2 (14.3%) |
| Minor bleeding | 2 (14.3%) |
| Major bleeding | 0 |
Values are median (IQR) or n (%); 4CH = four chamber view, DBP = diastolic blood pressure, DVT = deep vein thrombosis, HR = heart rate, PE = pulmonary embolism, NT-proBNP = N-terminal pro-B-type natriuretic peptide, LV = left ventricle, RV = right ventricle, SBP = systolic blood pressure, and TAPSE = tricuspid annular plane systolic excursion.